

# Agreement Form For Initiating Pr **MINT-EMTRICITABINE/ TENOFVIR for Pre-exposure Prophylaxis (PrEP) in adults at high risk of HIV-1 infection**

Individual Label

**Instructions: Review form with an HIV-negative person who is about to start or is taking MINT-EMTRICITABINE/TENOFVIR for a PrEP indication at each visit. File form in the person's medical record.**

MINT-EMTRICITABINE/TENOFVIR is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. The following factors may help to identify individuals at high risk:

- Has partner(s) known to be HIV-1 infected, or
- Engages in sexual activity within a high prevalence area or social network and one or more of the following:
  - Inconsistent or no condom use
  - Diagnosis of sexually transmitted infections
  - Exchange of sex for commodities (such as money, shelter, food, or drugs)
  - Use of illicit drugs, alcohol dependence
  - Incarceration
  - Partner(s) of unknown HIV-1 status with any of the factors listed above

## Healthcare Provider Agreement

By signing below, I signify my understanding of the risks and benefits of MINT-EMTRICITABINE/TENOFVIR for a PrEP indication and my obligation as a prescriber to educate the HIV-negative person about these risks, counsel the person on risk reduction, monitor the person appropriately, and report adverse events.

Specifically, I attest to having done the following:

- Confirmed the negative HIV-1 status of this person prior to starting MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Read the Product Monograph, including BOXED WARNINGS
- Discussed with the HIV-negative person the known safety risks with use of MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Reviewed the importance of adherence with a comprehensive prevention strategy, including practicing safer sex
- Discussed the importance of regular HIV-1 testing (at least every 3 months) while taking MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Reviewed the MINT-EMTRICITABINE/TENOFVIR Uninfected Individual Safety Brochure with the HIV-negative person at high risk prior to prescribing MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Completed the items on the Checklist for Prescribers: Initiation of MINT-EMTRICITABINE/TENOFVIR for Pre-Exposure Prophylaxis (PrEP)

## HIV-Negative Person Agreement

By signing below, I acknowledge that I have talked with my healthcare provider about the risks and benefits of MINT-EMTRICITABINE/TENOFOVIR to reduce the risk of getting HIV-1 infection, and I understand them clearly.

- My healthcare provider talked with me about the importance of follow-up HIV-1 testing, and I agree to have repeat HIV-1 screening tests (at least every 3 months) as scheduled by my healthcare provider
- My healthcare provider talked with me about the safety risks involved with using MINT-EMTRICITABINE/TENOFOVIR to reduce the risk of getting HIV-1 infection
- My healthcare provider talked with me about a complete prevention strategy and always practicing safer sex by using condoms correctly
- I will talk with my healthcare provider if I have any questions
- I have read the MINT-EMTRICITABINE/TENOFOVIR uninfected individual safety brochure

Please consult the Consumer Information section of the Product Monograph for information on warnings, precautions and side effects.

*Healthcare Provider's Signature*

*Date*

*HIV-Negative Person's Signature*

*Date*

MINT-EMTRICITABINE/TENOFOVIR is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

Consult the product monograph at [www.mintpharmaceuticals.com](http://www.mintpharmaceuticals.com) for contraindication, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-877-398-9696.